Cefoperazone
(Synonyms: 头孢哌酮) 目录号 : GC16501
A cephalosporin antibiotic
Cas No.:62893-19-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cefoperazone is a cephalosporin antibiotic which inhibits rMrp2-mediated [3H]E217βG uptake with an IC50 of 199 μM [1].
The inhibition profile for cefoperazone was biphasic with IC50, high and IC50, low values of 6.66 ± 3.23 μM and 3.88 ± 1.32 mM, respectively, indicating that cefoperazone may inhibit two binding sites that mediated [3H]E217βG transport [1]. Cefoperazone is a sterile, broad-spectrum, semisynthetic, parenteral cephalosporin antibiotic for intravenous or intramuscular administration. After intravenous administration of 2 g cefoperazone, levels in serum ranged from 202 μg/mL to 375 μg/mL depending on the period of drug administration. After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was111 μg/mL at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4 μg/mL.Cefoperazone is 90% bound to serum proteins.The apparent volume of distribution was 10 to 13L. The half-life of the drug varied from 1.6 to 2.4 hours, and the serum clearance was between 75 and 96 ml/min [2].
References:
[1]. Kato Y1,Takahara S,Kato S,Kubo Y,Sai Y,Tamai I,Yabuuchi H,Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics.Drug Metab Dispos.2008 Jun;36(6):1088-96. doi: 10.1124/dmd.107.019125. Epub 2008 Mar 13.
[2]. Craig WA,Gerber AU. Pharmacokinetics of cefoperazone: a review. Drugs.1981;22Suppl 1:35-45.
| Cas No. | 62893-19-0 | SDF | |
| 别名 | 头孢哌酮 | ||
| 化学名 | (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | ||
| Canonical SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O | ||
| 分子式 | C25H27N9O8S2 | 分子量 | 645.66 |
| 溶解度 | ≥ 64.6mg/mL in DMSO | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5488 mL | 7.744 mL | 15.488 mL |
| 5 mM | 0.3098 mL | 1.5488 mL | 3.0976 mL |
| 10 mM | 0.1549 mL | 0.7744 mL | 1.5488 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet